• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

QR678 Neo Effective in Treating Scalp Seborrheic Dermatitis


Significant improvement was shown in erythema and pruritis and patients reported high satisfaction.

In a recent study reported in the Journal of Cosmetic Dermatology, patients treated with intradermal administrations of QR678 Neo for scalp seborrheic dermatitis showed improvement in overall scalp condition.1 QR678 Neo is a combination of biomimetic polypeptides, vitamins, and minerals that have anti-inflammatory properties.



Forty patients (20 men, 20 women) ages 18 to 45 years with scalp seborrheic dermatitis participated in the single-arm, prospective study from October 2021 to October 2022. Disease severity ranged from moderate to severe and must have been present for at least 6 months to be included in the study.

Study Methods

At each session, 1-mL solution of QR678 Neo was administered through several tiny injections in the areas of the scalp showing signs of erythema, scaling, and pruritis. A total of 8 sessions were performed with 3 weeks between sessions. Patients were evaluated at baseline, after 4 sessions, and after 8 sessions by 2 dermatologists using the adherent scalp flaking score (ASFS).

Dermoscopic assessment using the Seborrheic Dermatitis Scalp Severity Index (SDSSI) was also used to quantitatively measure the clinical improvement of erythema, scaling, and arborizing vessels. At the end of the 8 treatments, patients answered 4 questions on their self-assessment of improvement.

Results of QR678 Neo Treatment

At baseline, ASFS mean score was 60. After 4 sessions the mean significantly decreased to 36 and after 8 sessions was 12, which was maintained for more than a year. Only 1 patient did not respond to treatments. The SDSSImean score at baseline was 11. Noticeable and significant improvement was seen after 4 sessions and the mean score decreased to 7. After 8 sessions the mean score was 2, and this was maintained for more than a year.

On a scale of 0 to 5, patients rated reduction in erythema and pruritis highly, with a mean score of 5. Reduction in inflammation and itchiness and reduction in flakes were rated a mean score of 4.5. The amount of noticeable improvement was also highly rated with a mean score of 4. Two patients reported a feeling of discomfort during administration, but only 1 patient reported an itchy scalp post-procedure.

In previous studies, QR678 Neo has been shown to be effective in improving hair growth in men and women. The results of this latest study demonstrate that QR678 Neo was an effective treatment for scalp seborrheic dermatitis and maintained results for 1 year without adverse events.


  1. Kapoor R, Shome D, Doshi K, Patel G, Tandel H, Kumar V. A newer approach in the treatment of seborrheic dermatitis with QR678® and QR678 Neo®—A prospective pilot study. J Cosmet Dermatol. 2023;00: 1-10. doi:10.1111/jocd.15957
Related Videos
© 2024 MJH Life Sciences

All rights reserved.